Mainz Biomed
Yahoo Finance • 4 months ago
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical c... Full story
Yahoo Finance • 5 months ago
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic.... Full story
Yahoo Finance • 7 months ago
mRNA Is Promising A Breakthrough In Fighting Cancer
mRNA Is Promising A Breakthrough In Fighting Cancer When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COV... Full story
Yahoo Finance • 10 months ago
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine Gardasil. However, Merck still recorded a net... Full story
Yahoo Finance • 10 months ago
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a cost-cutting program, internal restructuring an... Full story
Yahoo Finance • 11 months ago
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. as it continues its efforts to tap pharma innovations from China’s biotech industry. Although this... Full story
Yahoo Finance • 12 months ago
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces th... Full story
Yahoo Finance • last year
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
BERKELEY, Calif. and MAINZ, Germany, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces th... Full story
Yahoo Finance • last year
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023 ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced A... Full story
Yahoo Finance • last year
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (Nasdaq: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today annou... Full story
Yahoo Finance • last year
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
BERKELEY, Calif. and MAINZ, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (Nasdaq: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced t... Full story
Yahoo Finance • last year
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
BERKELEY, Calif. and MAINZ, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced toda... Full story
Yahoo Finance • last year
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
BERKELEY, Calif. and MAINZ, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced to... Full story
Yahoo Finance • last year
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
Former Natera Manager will oversee all aspects of sales and support in EMEA, ensuring the continued commercialization of ColoAlert® across the region BERKELEY, Calif. and MAINZ, Germany, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.... Full story
Yahoo Finance • last year
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
Results indicate a substantial and meaningful enhancement in the effectiveness of non-invasive colorectal cancer (CRC) screening, particularly for the detection of advanced adenomas, a precursor to CRC Clinical trial evaluating the Compan... Full story
Yahoo Finance • last year
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
BERKELEY, Calif. and MAINZ, Germany, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnostic company focused on early cancer detection, announced today it... Full story
Yahoo Finance • last year
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
BERKELEY, Calif. and MAINZ, Germany, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced to... Full story
Yahoo Finance • last year
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
BERKELEY, Calif. and MAINZ, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the... Full story
Yahoo Finance • last year
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81% Pulsus Group’s 4th International Conference on Gastroentero... Full story
Yahoo Finance • last year
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced t... Full story
